Question-and-Answer Session
Operator
(Operator Instructions) Your first question is from Bert Holten [Ph] with BMO Capital Markets.
Bert Holten - BMO Capital Markets
Holten is my last name. Hope all is well. My first question is with regard to the deal you’re referring to in Europe and the discussion surrounding that. Are you referring to one particular country there or how was the licensing going to progress there; and then I have another question.
Jennifer Good
Yes, so in Europe Bert, I think we would be some kind of a pan-European deal, we wouldn’t do country-by-country. I think in my comments what I was referring to is we’re not going to try to do a difficult deal and make one go over ex-U.S partner. We may do one deal in Canada, one in Europe, one in Asia, one in Latin America, the territories we can get licensed, but Europe I would think of as one territory.
Bert Holten - BMO Capital Markets
Okay. So we should expect you’re moving towards some sort of resolution with the party in one of those territories; whether it’s Canada or EU or another area?
Jennifer Good
Yes, this is an active process as we speak. I’m very happy with how discussions are going and as I reiterated, I expect we’ll have a deal signed by the end of the first half, so we’re closing in on it.
Bert Holten - BMO Capital Markets
Okay great. And just if you could give us an update on the patent situation again, the elephant in the room here with regard to Opana ER, and then may be if you can discuss anything with regard to any incremental data or information you could provide on combinations that are being contemplated with Opana and other analgesics? Thanks.
Jennifer Good
Your favorite question which I can never answer, but I can answer the first part of that. We have two key efforts underway here, that we are involved and to protect Opana ER, the patent prosecution and patent litigation.
On the patent prosecution side, we continue our efforts to prosecute additional TIMERx patent. I think even more importantly, Endo is aggressively prosecuting several clinical patents. They’ve got a handful of those patents at the PTO review board and we do expect the decision on those by the end of this year.
On the litigation side, we still have three ongoing suits as we’ve disclosed, we did settle with Actavis. The current trial date for that litigation is set for the spring of 2010; and Bert, your question on life cycle management, I hate to do this because I know you are looking for information there, but it’s just not appropriate for a partner to answer marketing strategy questions. So I’d encourage you to call Endo and see if you can get some information there.
- To read the full transcript on Seeking Alpha, click here »
